250 related articles for article (PubMed ID: 1794035)
1. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.
Chrisp P; Sorkin EM
Drugs Aging; 1991; 1(6):487-509. PubMed ID: 1794035
[TBL] [Abstract][Full Text] [Related]
2. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
Plosker GL; Brogden RN
Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
Khan MS; O'Brien A
Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
[TBL] [Abstract][Full Text] [Related]
4. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
5. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
Berges R; Bello U
Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of depot leuprorelin.
Periti P; Mazzei T; Mini E
Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
[TBL] [Abstract][Full Text] [Related]
8. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist.
Tsushima T; Nasu Y; Saika T; Maki Y; Noda M; Suyama B; Yamato T; Kumon H
Urol Int; 2001; 66(3):135-9. PubMed ID: 11316974
[TBL] [Abstract][Full Text] [Related]
9. Leuprorelin acetate in prostate cancer: a European update.
Persad R
Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
[TBL] [Abstract][Full Text] [Related]
10. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.
Fornara P; Jocham D
Urol Int; 1996; 56 Suppl 1():18-22. PubMed ID: 8776813
[TBL] [Abstract][Full Text] [Related]
11. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.
Sethi R; Sanfilippo N
Clin Interv Aging; 2009; 4():259-67. PubMed ID: 19554097
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group.
Kienle E; Lübben G
Urol Int; 1996; 56 Suppl 1():23-30. PubMed ID: 8776814
[TBL] [Abstract][Full Text] [Related]
13. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer.
Perez-Marrero R; Tyler RC
Expert Opin Pharmacother; 2004 Feb; 5(2):447-57. PubMed ID: 14996640
[TBL] [Abstract][Full Text] [Related]
14. Luteinising hormone releasing hormone analogues in the treatment of prostate cancer.
Gommersall LM; Hayne D; Shergill IS; Arya M; Wallace DM
Expert Opin Pharmacother; 2002 Dec; 3(12):1685-92. PubMed ID: 12472366
[TBL] [Abstract][Full Text] [Related]
15. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
Williams G; Lindsay S; Bowsher WG
Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
[TBL] [Abstract][Full Text] [Related]
16. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
Bolton EM; Lynch T
BJU Int; 2018 Sep; 122(3):371-383. PubMed ID: 29438592
[TBL] [Abstract][Full Text] [Related]
17. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
Brogden RN; Faulds D
Drugs Aging; 1995 Apr; 6(4):324-43. PubMed ID: 7613021
[TBL] [Abstract][Full Text] [Related]
18. 3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. German Leuprorelin Study Group.
Bischoff W
J Int Med Res; 1990; 18 Suppl 1():103-13. PubMed ID: 2108882
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer.
O' Brien A; Hibberd M
J Int Med Res; 1990; 18 Suppl 1():57-68. PubMed ID: 2108886
[TBL] [Abstract][Full Text] [Related]
20. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
Tomura A; Kuroiwa S; Okada M; Abe F
Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
